Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding.
作者信息
Agúndez José A G, Martínez Carmen, García-Martín Elena, Ladero José M
出版信息
Gastroenterology. 2007 Dec;133(6):2071-2; author reply 2072-3. doi: 10.1053/j.gastro.2007.10.015.
PMID:18054585
Abstract
摘要
相似文献
1
Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding.
Gastroenterology. 2007 Dec;133(6):2071-2; author reply 2072-3. doi: 10.1053/j.gastro.2007.10.015.
2
Impact of CYP2C9 genotype on pharmacokinetics: are all NSAIDs the same?
Gastroenterology. 2007 Dec;133(6):2073-4; author reply 2074-5. doi: 10.1053/j.gastro.2007.10.019.
3
CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin.
Clin Pharmacol Ther. 2010 Jun;87(6):693-8. doi: 10.1038/clpt.2010.33. Epub 2010 May 5.
4
Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.
Pharmacogenet Genomics. 2008 Jan;18(1):37-43. doi: 10.1097/FPC.0b013e3282f305a9.
5
CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
J Dig Dis. 2008 May;9(2):79-83. doi: 10.1111/j.1751-2980.2008.00326.x.
6
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Gastroenterology. 2007 Aug;133(2):465-71. doi: 10.1053/j.gastro.2007.05.025. Epub 2007 May 21.
7
Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.
Br J Pharmacol. 2004 Jan;141(2):205-8. doi: 10.1038/sj.bjp.0705623. Epub 2004 Jan 5.
8
Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review.
Pharmacogenet Genomics. 2011 Jul;21(7):357-64. doi: 10.1097/FPC.0b013e328346d2bb.
9
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20. doi: 10.1517/17425250902970998.
10
CYP2C9 polymorphisms: considerations in NSAID therapy.
Curr Opin Drug Discov Devel. 2009 Jan;12(1):108-14.
引用本文的文献
1
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb.
Zotero 插件